Nuwellis, Inc. (NUWE)
Market Cap | 2.10M |
Revenue (ttm) | 8.90M |
Net Income (ttm) | -19.93M |
Shares Out | 515.74K |
EPS (ttm) | -257.95 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 274,208 |
Open | 4.960 |
Previous Close | 4.870 |
Day's Range | 3.980 - 5.130 |
52-Week Range | 3.980 - 98.350 |
Beta | 0.49 |
Analysts | Hold |
Price Target | n/a |
Earnings Date | Aug 6, 2024 |
About NUWE
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Aus... [Read more]
Financial Performance
In 2023, Nuwellis's revenue was $8.86 million, an increase of 3.76% compared to the previous year's $8.54 million. Losses were -$22.63 million, 55.8% more than in 2022.
Financial StatementsNews
Nuwellis Announces Reverse Stock Split
MINNEAPOLIS, June 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload...
Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™
MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the recent g...
DaVita, Nuwellis Extend Pilot Collaboration for Aquadex
DaVita DVA recently extended the pilot phase of a previously announced supply and collaboration agreement with Nuwellis NUWE until Aug 31, 2024.At the conclusion of the pilot phase, DaVita may extend ...
Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase
Pilot Collaboration for Aquadex® Ultrafiltration Therapy for Adult Patients with Congestive Heart Failure is extended to August 31, 2024 Pilot Collaboration for Aquadex® Ultrafiltration Therapy for Ad...
Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida
MINNEAPOLIS, May 14, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the launch of...
Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy
MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced a new purchas...
Nuwellis, Inc. Announces First Quarter 2024 Financial Results
MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial resu...
Nuwellis Announces Closing of $2.7 Million Public Offering
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overloa...
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it wi...
Nuwellis Announces Pricing of $2.7 Million Public Offering
MINNEAPOLIS, April 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overloa...
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
- Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failure hospitalizations compared to intravenous loop diuretics- Artificial in...
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital Accounts Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding ...
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will...
Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its distribu...
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective February 20, 2024, the Company's independent directors approved equity awards under Nuwelli...
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don't respond to diuretics Early findings suggest Aquadex as a poten...
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies Specialty catheter provides alternative peripheral access for ultra...
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results
MINNEAPOLIS, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial r...
Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023
MINNEAPOLIS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its thi...
Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
MINNEAPOLIS, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, ...
Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
MINNEAPOLIS, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, ...
Nuwellis Provides Regulatory Update on SeaStar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
MINNEAPOLIS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (Nuwellis), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced...
Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase
MINNEAPOLIS, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that Pres...
Nuwellis, Inc. Announces Second Quarter 2023 Financial Results
MINNEAPOLIS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial r...